SCHEMBL298752

SCHEMBL298752

Cn1cc(-c2cnc3[nH]cc(C(=O)c4cc(NS(=O)(=O)c5cccc(OC(F)(F)F)c5)ccc4F)c3c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 4/20 0.44
CYP3A4 P08684 1/20 0.44
KIT P10721 1/20 0.44
PIK3CA P42336 1/20 0.43
ALPL P05186 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 2/20 0.41
ABL1 P00519 1/20 0.41
CYP2C9 P11712 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298196 0.90 PAK1 (0.44) PAK1CYP3A4KITPIK3CAALPL
SCHEMBL298700 0.90 CYP3A4 (0.54) PAK1CYP3A4PIK3CACYP2D6CYP2C19
SCHEMBL297485 0.89 ALK (0.49) PAK1CYP3A4KITPIK3CACYP2D6
SCHEMBL298709 0.88 PAK1 (0.48) PAK1CYP3A4PIK3CACYP2D6CYP2C19
SCHEMBL10283684 0.88 CYP3A4 (0.51) PAK1CYP3A4PIK3CACYP2D6CYP2C19
SCHEMBL297209 0.85 CYP3A4 (0.51) PAK1CYP3A4PIK3CACYP2C19CYP2C9
SCHEMBL299292 0.85 CYP3A4 (0.50) PAK1CYP3A4PIK3CACYP2D6CYP2C19
SCHEMBL298324 0.85 CYP3A4 (0.47) PAK1CYP3A4KITPIK3CACYP2C19
SCHEMBL296823 0.85 PIK3CA (0.49) PAK1CYP3A4PIK3CACYP2C19CYP2C9
SCHEMBL299321 0.83 PAK1 (0.45) PAK1KITPIK3CAALPLABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF PAK1 290/4885CYP3A4 3611/4885KIT 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.